{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:54:20Z","timestamp":1769550860326,"version":"3.49.0"},"reference-count":30,"publisher":"Pharmaceutical Society of Japan","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2018,5,1]]},"DOI":"10.1248\/bpb.b17-01041","type":"journal-article","created":{"date-parts":[[2018,4,30]],"date-time":"2018-04-30T22:26:07Z","timestamp":1525127167000},"page":"663-669","source":"Crossref","is-referenced-by-count":8,"title":["Development and Evaluation of Antibody Proteomics Technology for Rapid and Comprehensive Identification of Potential Biomarkers and Therapeutic Targets"],"prefix":"10.1248","volume":"41","author":[{"given":"Kazuya","family":"Nagano","sequence":"first","affiliation":[{"name":"Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature<\/i>, 429<\/b>, 464\u2013468 (2004).","DOI":"10.1038\/nature02626"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat. Rev. Drug Discov.<\/i>, 12<\/b>, 581\u2013594 (2013).","DOI":"10.1038\/nrd4051"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Hanash S. Disease proteomics. Nature<\/i>, 422<\/b>, 226\u2013232 (2003).","DOI":"10.1038\/nature01514"},{"key":"4","unstructured":"4) Kavallaris M, Marshall GM. Proteomics and disease: opportunities and challenges. Med. J. Aust.<\/i>, 182<\/b>, 575\u2013579 (2005)."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Kaufmann H, Bailey JE, Fussenegger M. Use of antibodies for detection of phosphorylated proteins separated by two-dimensional gel electrophoresis. Proteomics<\/i>, 1<\/b>, 194\u2013199 (2001).","DOI":"10.1002\/1615-9861(200102)1:2<194::AID-PROT194>3.0.CO;2-K"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Au NH, Gown AM, Cheang M, Huntsman D, Yorida E, Elliott WM, Flint J, English J, Gilks CB, Grimes HL. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl. Immunohistochem. Mol. Morphol.<\/i>, 12<\/b>, 240\u2013247 (2004).","DOI":"10.1097\/00129039-200409000-00010"},{"key":"7","unstructured":"7) Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M. Tissue microarray: a new technology for amplification of tissue resources. Cancer J.<\/i>, 7<\/b>, 24\u201331 (2001)."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Imai S, Mukai Y, Nagano K, Shibata H, Sugita T, Abe Y, Nomura T, Tsutsumi Y, Kamada H, Nakagawa S, Tsunoda S. Quality enhancement of the non-immune phage scFv library to isolate effective antibodies. Biol. Pharm. Bull.<\/i>, 29<\/b>, 1325\u20131330 (2006).","DOI":"10.1248\/bpb.29.1325"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Imai S, Nagano K, Yoshida Y, Okamura T, Yamashita T, Abe Y, Yoshikawa T, Yoshioka Y, Kamada H, Mukai Y, Nakagawa S, Tsutsumi Y, Tsunoda S. Development of an antibody proteomics system using a phage antibody library for efficient screening of biomarker proteins. Biomaterials<\/i>, 32<\/b>, 162\u2013169 (2011).","DOI":"10.1016\/j.biomaterials.2010.09.030"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Nagano K, Imai S, Zhao X, Yamashita T, Yoshioka Y, Abe Y, Mukai Y, Kamada H, Nakagawa S, Tsutsumi Y, Tsunoda S. Identification and evaluation of metastasis-related proteins, oxysterol binding protein-like 5 and calumenin, in lung tumors. Int. J. Oncol.<\/i>, 47<\/b>, 195\u2013203 (2015).","DOI":"10.3892\/ijo.2015.3000"},{"key":"11","unstructured":"11) Yamashita T, Okamura T, Nagano K, Imai S, Abe Y, Nabeshi H, Yoshikawa T, Yoshioka Y, Kamada H, Tsutsumi Y, Tsunoda S. Rho GDP-dissociation inhibitor alpha is associated with cancer metastasis in colon and prostate cancer. Pharmazie<\/i>, 67<\/b>, 253\u2013255 (2012)."},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Yamashita T, Nagano K, Kanasaki S, Maeda Y, Furuya T, Inoue M, Nabeshi H, Yoshikawa T, Yoshioka Y, Itoh N, Abe Y, Kamada H, Tsutsumi Y, Tsunoda S. Annexin A4 is a possible biomarker for cisplatin susceptibility of malignant mesothelioma cells. Biochem. Biophys. Res. Commun.<\/i>, 421<\/b>, 140\u2013144 (2012).","DOI":"10.1016\/j.bbrc.2012.03.144"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Nagano K, Kanasaki S, Yamashita T, Maeda Y, Inoue M, Higashisaka K, Yoshioka Y, Abe Y, Mukai Y, Kamada H, Tsutsumi Y, Tsunoda S. Expression of Eph receptor A10 is correlated with lymph node metastasis and stage progression in breast cancer patients. Cancer Med.<\/i>, 2<\/b>, 972\u2013977 (2013).","DOI":"10.1002\/cam4.156"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Nagano K, Maeda Y, Kanasaki S, Watanabe T, Yamashita T, Inoue M, Higashisaka K, Yoshioka Y, Abe Y, Mukai Y, Kamada H, Tsutsumi Y, Tsunoda S. Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers. J. Control. Release<\/i>, 189<\/b>, 72\u201379 (2014).","DOI":"10.1016\/j.jconrel.2014.06.010"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Nagano K, Yamashita T, Inoue M, Higashisaka K, Yoshioka Y, Abe Y, Mukai Y, Kamada H, Tsutsumi Y, Tsunoda S. Eph receptor A10 has a potential as a target for a prostate cancer therapy. Biochem. Biophys. Res. Commun.<\/i>, 450<\/b>, 545\u2013549 (2014).","DOI":"10.1016\/j.bbrc.2014.06.007"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin.<\/i>, 55<\/b>, 74\u2013108 (2005).","DOI":"10.3322\/canjclin.55.2.74"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat. Rev. Cancer<\/i>, 3<\/b>, 55\u201363 (2003).","DOI":"10.1038\/nrc967"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Rochefort H, Capony F, Garcia M. Cathepsin D: a protease involved in breast cancer metastasis. Cancer Metastasis Rev.<\/i>, 9<\/b>, 321\u2013331 (1990).","DOI":"10.1007\/BF00049522"},{"key":"19","unstructured":"19) Koga F, Kihara K, Neckers L. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res.<\/i>, 29<\/b>, 797\u2013807 (2009)."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell<\/i>, 118<\/b>, 277\u2013279 (2004).","DOI":"10.1016\/j.cell.2004.07.011"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Torosian M, Charland S, Lappin J. Biochemical modulation of tumor-growth, metastasis and host metabolism. Oncol. Rep.<\/i>, 2<\/b>, 1141\u20131145 (1995).","DOI":"10.3892\/or.2.6.1141"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Teraoka S, Kyoizumi S, Seyama T, Yamakido M, Akiyama M. Scid mice model for the in-vivo<\/i> study of human oncotherapy-studies on the growth and metastasis of human lung-cancer. Int. J. Oncol.<\/i>, 5<\/b>, 501\u2013508 (1994).","DOI":"10.3892\/ijo.5.3.501"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Hirai K, Shimada H, Ogawa T, Taji S. The spread of human lung cancer cells on collagens and its inhibition by type III collagen. Clin. Exp. Metastasis<\/i>, 9<\/b>, 517\u2013527 (1991).","DOI":"10.1007\/BF01768580"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Heintz NH, Janssen-Heininger YM, Mossman BT. Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am. J. Respir. Cell Mol. Biol.<\/i>, 42<\/b>, 133\u2013139 (2010).","DOI":"10.1165\/rcmb.2009-0206TR"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Rom WN, Travis WD, Brody AR. Cellular and molecular basis of the asbestos-related diseases. Am. Rev. Respir. Dis.<\/i>, 143<\/b>, 408\u2013422 (1991).","DOI":"10.1164\/ajrccm\/143.2.408"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Berghmans T, Paesmans M, Lalami Y, Louviaux I, Luce S, Mascaux C, Meert AP, Sculier JP. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer<\/i>, 38<\/b>, 111\u2013121 (2002).","DOI":"10.1016\/S0169-5002(02)00180-0"},{"key":"27","unstructured":"27) Mintzer DM, Kelsen D, Frimmer D, Heelan R, Gralla R. Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat. Rep.<\/i>, 69<\/b>, 711\u2013712 (1985)."},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Lin SX, Chen J, Mazumdar M, Poirier D, Wang C, Azzi A, Zhou M. Molecular therapy of breast cancer: progress and future directions. Nat. Rev. Endocrinol.<\/i>, 6<\/b>, 485\u2013493 (2010).","DOI":"10.1038\/nrendo.2010.92"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat. Rev. Clin. Oncol.<\/i>, 7<\/b>, 683\u2013692 (2010).","DOI":"10.1038\/nrclinonc.2010.154"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Huber KE, Carey LA, Wazer DE. Breast cancer molecular subtypes in patients with locally advanced disease: impact on prognosis, patterns of recurrence, and response to therapy. Semin. Radiat. Oncol.<\/i>, 19<\/b>, 204\u2013210 (2009).","DOI":"10.1016\/j.semradonc.2009.05.004"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/41\/5\/41_b17-01041\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T03:55:56Z","timestamp":1525492556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/41\/5\/41_b17-01041\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,1]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b17-01041","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,1]]}}}